NCT05731752View on ClinicalTrials.gov

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

HX009

The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciense, Beijing

Sponsors
All Listed Sponsors
lead

Hangzhou Hanx Biopharmaceuticals, Ltd.

INDUSTRY

NCT05731752 - Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter